Flurpiridaz F 18 | Myocardial Infarction | HongKong DengYue Medicine

Flurpiridaz F 18 Application Scope

Flurpiridaz F 18 is a positron emission tomography (PET) myocardial perfusion imaging (MPI) tracer used in adult patients with known or suspected coronary artery disease (CAD) to evaluate myocardial ischemia and infarction under rest or stress (pharmacologic or exercise) conditions.

Flurpiridaz F 18 Characteristics

Ingredients:

• Active ingredient: Flurpiridaz F 18 (a fluorine-18-labeled small molecule)

• Chemical formula: C₁₈H₂₂ClFN₂O₃

• Contains ethanol (max 337 mg anhydrous ethanol per dose).

Properties:

• Type: Radiopharmaceutical diagnostic agent

• Mechanism of Action: Binds to mitochondrial complex 1 (MC-1) in viable myocardium, with uptake proportional to blood flow.

• Half-life: 109.8 minutes (allowing wider distribution compared to other PET tracers).

• Radiation dose: Effective dose ~6.4 mSv (lower than SPECT MPI).

Packaging Specification:

• Injectable solution in a shielded multiple-dose vial

• Strength: 5-55 mCi/mL (190-2,050 MBq/mL) at end of synthesis.

Storage:

• Store at 2-30°C (36-86°F) within radiation shielding

• Short excursions permitted: -20°C (-4°F) for ≤2 hr or 50°C (122°F) for ≤8 hr.

Expiry Date:

• 8 hours post-synthesis or when radioactivity falls below required levels.

Executive Standard:

• FDA-approved for PET MPI (approved September 27, 2024).

Approval Number:

• NDC: 0407-8787-01 (as provided for billing).

Date of Revision:

• Not explicitly stated in sources; latest FDA approval was in September 2024.

Manufacturer:

• GE Healthcare.

Guidelines for the Use of Flurpiridaz F 18

Dosage and Administration:

• Rest imaging: 2.5–3 mCi (93–111 MBq)

• Stress imaging (pharmacologic): 6–6.5 mCi (222–241 MBq)

• Stress imaging (exercise): 9–9.5 mCi (333–342 MBq)

• Protocols:

  • Same-day: Minimum 30 min (pharmacologic) or 60 min (exercise) between doses

  • 2-day: Separate rest and stress imaging days.

Adverse Reactions:

• Common (≥2%): Dyspnea, headache, angina pectoris, chest pain, fatigue, ST-segment changes, flushing, nausea, abdominal pain, dizziness, arrhythmia.

Contraindications:

• None absolute, but caution with stress testing (risk of MI, arrhythmia, hypotension).

Precautions:

• Radiation safety: Minimize exposure; advise hydration and frequent voiding post-administration.

• Pregnancy/Lactation:

  • Avoid in pregnancy unless necessary (ethanol content; radiation risk)

  • Discontinue breastfeeding for ≥8 hours post-dose.

Flurpiridaz F 18 Interactions

• Drug Interactions: No specific drug interaction studies have been conducted. Advise patients to inform their healthcare provider about all medications they are taking, including prescription and over-the-counter drugs, vitamins, and herbal supplements.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.